Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling

被引:18
|
作者
Sung, YK [1 ]
Hwang, SY [1 ]
Farooq, M [1 ]
Kim, JC [1 ]
Kim, MK [1 ]
机构
[1] Kyungpook Natl Univ, Sch Med, Dept Immunol, Taegu 700422, South Korea
来源
EXPERIMENTAL AND MOLECULAR MEDICINE | 2003年 / 35卷 / 04期
关键词
glypican-3; growth suppression; hepatoma; insulin-like growth factor 2;
D O I
10.1038/emm.2003.34
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glypican-3 (GPC3) encodes a cell-surface heparan-sulfate proteoglycan and its expression is frequently silenced in ovarian cancer, mesotheliomas, and breast cancer cell lines and ectopic expression of GPC3 inhibited the growth of these cells, suggesting that GPC3 plays a negative role in cell proliferation. In contrast, up-regulation of GPC3 is often observed in hepatoma, neuroblastoma, and Wilms' tumor. Whether GPC3 plays the same growth inhibitory role in these tumors remains to be studied. Here we report that antisense-mediated knockdown of GPC3 in the HepG2 hepatoma cells significantly promotes the growth of hepatoma cells. In addition, we show that this growth promotion is independent of insulin-like growth factor 2 (IGF2) signaling. Our data suggest that GPC3 plays a growth-suppressing role in hepatoma and provide cell biological evidence inconsistent with the hypothesis that GPC3 acts as a growth suppressor by downregulating IGF2.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 50 条
  • [1] Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling
    Young Kwan Sung
    Sung Young Hwang
    Mohammad Farooq
    Jung-Chul Kim
    Moon Kyu Kim
    Experimental & Molecular Medicine, 2003, 35 : 257 - 262
  • [2] Glypican-3 is a novel inhibitor of insulin-like growth factor signaling
    Filmus, J
    Song, H
    Shi, W
    Gonzalez, AD
    Kaya, M
    Cano-Gauci, D
    MEDICINA-BUENOS AIRES, 1999, 59 (05) : 546 - 546
  • [3] 5/rat glypican-3 binds fibroblast growth factor-2 not to insulin-like growth factor-2
    Song, HH
    Shi, W
    Filmus, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (12) : 7574 - 7577
  • [4] INHIBITION OF INSULIN DEGRADATION BY INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II IN HUMAN HEPATOMA (HEPG2) CELLS
    KELLER, S
    SCHMID, C
    ZAPF, J
    FROESCH, ER
    ACTA ENDOCRINOLOGICA, 1989, 121 (02): : 279 - 285
  • [5] Factors regulating insulin-like growth factor binding protein-3 secretion from human hepatoma (HepG2) cells
    Kalme, T
    Loukovaara, M
    Koistinen, H
    Koistinen, R
    Seppälä, M
    Leinonen, P
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 78 (02): : 131 - 135
  • [6] Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway
    Chen, Yihui
    Zhong, Wei
    Chen, Baohua
    Yang, Chuanyu
    Zhou, Song
    Liu, Jing
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (03) : 2922 - 2928
  • [7] SURAMIN INHIBITS GROWTH AND YET PROMOTES INSULIN-LIKE GROWTH FACTOR-II EXPRESSION IN HEPG2 CELLS
    KRAFT, A
    REID, LM
    ZVIBEL, I
    CANCER RESEARCH, 1993, 53 (03) : 652 - 657
  • [8] Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway
    Cheng, Wei
    Tseng, Chia-Jen
    Lin, Tom T. C.
    Cheng, I.
    Pan, Hung-Wei
    Hsu, Hey-Chi
    Lee, Yu-May
    CARCINOGENESIS, 2008, 29 (07) : 1319 - 1326
  • [9] Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor (Review)
    Resnicoff, M
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 1998, 1 (05) : 883 - 888